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Cell-derived microparticles (MPs) are vesicles budding from cellular plasma membrane under stress or 
activation, range from 0.1 to 1 micron in size. MPs, which are distinct from the smaller exosomes, are found to 
be important in cell-cell communication through transferring cargo such as RNAs, proteins, and lipids from 
parent cells to target cells. We work with megakaryocytic MPs (MkMPs), which are the most abundant MPs in 
circulating blood. MkMPs are derived from megakaryocytes (Mks) which are derived from hematopoietic stem 
and progenitor cells (HSPCs). We have previously shown that MkMPs target HSPCs to program them into 
generating megakaryocytes (Mks) leading to platelet generation without addition of thrombopoietin. The 
recognition is specific for HSPCs and the outcomes specific for Mk and platelet generation. We have also shown 
that uptake of MkMPs by HSPCs is though both some endocytotic process had membrane fusion. We carried 
out studies to enhance our understanding of the process of target recognition and specificity with the ultimate 
goal of using MkMPs for cell therapy and cargo-delivery applications.  Using various inhibitors, we show that 
macropinocytosis and lipid rafts play an important role in the uptake of MkMPs by HSPCs. We also describe that 
MkMPs target and enter HSPCs in the HSPC uropod (“tail”), which helped us identify the specific surface 
antigens, mostly on HSPCs, that are responsible of mediating the recognition and uptake process of MkMPs. To 
pursue therapeutic applications, we present data involving transfusion of MkMPs in a murine model with and 
without induced thrombocytopenia. We also discuss methods for loading MkMPs with exogenous cargo for 
delivery to HSPCs, and the development of tools to visualize the cargo delivery.  
 
